This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Adding the measurement that post #30 says would settle it.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
Happy to expand any of that if it is the useful part.
Post #28 describes the usual case. This is about the unusual one.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
On analysis of a small molecule: purity by chromatography against a reference standard, identity by mass and by spectroscopy, and residual solvents by a headspace method. That is a much more complete picture than a peptide certificate usually offers.
That is my reading. Someone else read the same page differently and was reasonable.
Noted, and I have changed what I was going to do on the strength of it.
The arithmetic in post #33 is right; the assumption feeding it is the part to check.
Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
Second-hand, so weight it accordingly.
Post #36 put the caveat in the right place and I want to underline it.
The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.
Posting it because the silence on this was starting to look like agreement.
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
It is a small point and it changes the answer, which is an awkward combination.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
Adding it in case it saves somebody the afternoon it cost me.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
For what it is worth, the same held on the two occasions I checked.
The most useful thing anyone has posted about SOUL trial and oral semaglutide in this category was a table of what had been measured and by whom. That is what I would want again.
Post #41 is right about the mechanism and I think understates the practical bit.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
If the premise is wrong, everything after it is decoration.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
I had written a reply contradicting post #46 and deleted it. Here is what survived.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
Confirming post #46 from a second method, which matters more than confirming it from a second person.
Adding a null result on SOUL trial and oral semaglutide. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Building on post #48 rather than restating it.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
Take the reasoning and check the arithmetic; I do not always get it right.
Post #52 answers the question as asked. The question underneath it is different.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
The honest answer is that it depends, and here is what it depends on.
I read post #50 twice before replying, because I had assumed the opposite.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
That has held every time I have looked, which is not the same as always.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
That is what I would do. It may not be what is correct.
Noted, and thank you for writing it out rather than summarising it.
Building on post #56 rather than restating it.
Genuine question rather than a rhetorical one: has anyone here actually observed SOUL trial and oral semaglutide, as opposed to read about it? The thread is long and I cannot tell.
Post #59 put the caveat in the right place and I want to underline it.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.